A year ago, Wall Street’s consensus price target for NuScale Power (NYSE: SMR) stood at $40.84; by October 22 it had cratered to $11.07, a 73% compression that tells its own story.
That target reduction unfolded as the stock itself closed at $5.38 on October 22, down 39% over the prior month alone, while peer Oklo (NYSE: OKLO) shed 33% across the same stretch.
For context, the Nasdaq 100 gave up just 6% during that period, underscoring how severely sentiment has turned against advanced nuclear developers as a group.
The math produces an eye-catching number: NuScale trades roughly 51% below its consensus analyst target, implying theoretical upside of about 106% over the next twelve months.
Whether that gap represents genuine value or simply reflects how quickly forecasts are still being revised downward is the central question confronting investors right now.
The sell-off accelerated in mid-October when hotter-than-expected September inflation data pushed the 10-year Treasury yield to 5.26%, punishing companies whose profitability remains years in the future.
NuScale dropped 10% in that single session on October 14, with Oklo sliding 8.6%, as higher financing costs magnified doubts about projects that require enormous upfront capital.
Analyst downgrades piled on throughout the month: UBS moved to Sell in September with a $6 target, RBC trimmed to $7, and Barclays downgraded to Underweight on October 20, cutting its target to $5 from $11 and citing commercial delays and contract uncertainty.
Citi subsequently set its target at $4, and Truist landed at $8, leaving NuScale with a wall of skepticism from major institutions even as management works to sign definitive agreements.
CNBC’s Mad Money host Jim Cramer framed the broader mood on October 1, arguing that “Fermi marked the top for all sorts of long shot nuclear energy companies,” capturing how quickly enthusiasm for the sector reversed.
The commercial uncertainty is most acute for NuScale, whose partnership with ENTRA1 Energy and the Tennessee Valley Authority has yet to produce binding power purchase agreements that would convert project ambitions into contracted revenue.
A manufacturing agreement signed with Doosan Enerbility on October 29 advanced production of key reactor components, but it did nothing to resolve the more fundamental question of whether customers will commit at the scale necessary to justify current projections.
UBS has projected construction timelines of more than five years, cash consumption approaching $700 million between 2026 and 2028, and continued losses extending through 2030, a timeline that demands patient capital and tolerance for dilution.
NuScale’s diluted share count ballooned from roughly 51 million in fiscal 2022 to 164 million in fiscal 2025, illustrating how heavily the company has leaned on equity issuance to fund its development runway.
The company did end June with $1.9 billion in cash and investments, providing enough liquidity to sustain operations through the near term without an immediate financing crisis.
Oklo’s position looks comparatively stronger on execution evidence: its Groves Isotope Test Reactor achieved first criticality in August, establishing a controlled nuclear chain reaction less than a year after breaking ground.
That milestone does not represent a commercial power plant, but it offers a tangible proof point that distinguishes Oklo from NuScale at a moment when investors are demanding demonstrated progress rather than project announcements.
NuScale’s November 5 earnings call represents the next significant opportunity for management to address commercial progress, though analysts and investors will be watching closely for any movement on definitive customer commitments.
Until those agreements materialize, NuScale looks less like a discounted opportunity and more like a speculative position where the risk of further target reductions outweighs the apparent gap between price and consensus.
